Immunotherapy duo aims to boost cervical cancer treatment before chemoradiation
NCT ID NCT07613567
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to chemotherapy before standard chemoradiation can help people with locally advanced cervical cancer live longer without the disease getting worse. About 486 adults aged 18-75 with stage III-IVA cervical cancer will be enrolled. The approach combines neoadjuvant immunotherapy and chemo, followed by immunotherapy with radiation, compared to standard chemoradiation alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could vitamin d predict cervical cancer treatment success?
- Can a triple-threat approach wipe out cervical cancer before surgery?
- Particle beam and immune therapy join forces against cervical cancer
- Dual immunotherapy plus chemo may shrink cervical tumors before surgery
- Protein clues may predict cervical cancer return
- Intermittent fasting tested to ease radiation side effects in cancer patients